Abstract: The invention concerns heterocyclic compounds of the general formula (I) in which A, B, R, R.sup.2, R.sup.3, W, Y, Z.sup.1, Z.sup.2 and r are as defined in the description, methods of preparing them and their use as inhibitors of thrombocyte aggregation, the metastization of carcinoma cells and the binding of osteoclasts on bone surfaces.

Abstract: The present invention relates to compounds of the general formula I ##STR1## in which R, R.sup.1 to R.sup.4, r, Y, Z and W are defined as indicated in the description, a process for their preparation and their use as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.

Abstract: Phenylimidazolidine derivatives of the general formula I ##STR1## in which, for example, Y denotes --CH.sub.2 --CH.sub.2 --CO--r denotes 0 to 3Z denotes oxygenW denotes hydroxylR.sup.1 denotes --NH--C(.dbd.NH)--NH.sub.2R, R.sup.2, R.sup.3 denote hydrogenR.sup.4 denotes --CO--NHR.sup.5,where --NH--R.sup.5 represents an .alpha.-amino acid radical, have useful pharmacological properties such as inhibition of platelet aggregation and osteoclast binding to the bone surfaces.

Abstract: Aspartic acid derivatives of the formula ##STR1## in which X denotes, for example, ##STR2## and R denotes, for example, cyclohexylamino, have useful pharmacological properties.

Abstract: The present invention relates to 2,4-dioxoimidazolidine compounds of the formula I ##STR1## a process for their preparation and their use as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.

Abstract: The invention relates to compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and Y have the meanings indicated in Claim 1, to processes for their preparation and their use as active pharmacological substances.

Abstract: The present invention relates to a process for the preparation of pyrrole derivatives of the general formula I ##STR1## by reaction of a compound of the general formula III ##STR2## where R, R.sup.1 and R.sup.2 are defined as specified in claim 1, in a Vilsmeier reaction. The reaction is carried out in an easily degradable solvent, the reaction product is isolated with the aid of a water-miscible extractant and is purified by high-vacuum distillation in the short path evaporator.

Abstract: 2-(Aminoalkyl)pyrrolealdehydes of the general formula I ##STR1## in which R: denotes hydrogen, alkyl;R.sup.1 : denotes, for example, hydrogen, alkyl, phenyl;R.sup.2 and R.sup.3 : denote, for example, hydrogen, alkyl or alkanoyl, have useful pharmacological properties.

Abstract: Pyrrolealdehydes of the formula I ##STR1## wherein R and R.sup.1 independently of one another denote hydrogen or alkyl with 1 to 4 C atoms, R.sup.2 denotes alkyl, which is substituted by acylamino of the formula II ##STR2## wherein X stands for an oxygen or sulphur atom and R.sup.3 denotes hydrogen, optionally substituted alkyl or alkylamino, cycloalkyl with 5 to 7 C atoms, optionally substituted phenyl, an amino group or an optionally substituted phenylamio group, and pharmaceutically acceptable acid addition salts thereof, and wherein R.sup.3 cannot represent hydrogen if R and R.sup.1 denote hydrogen and the pyrrole ring is formylated in the 3-position, their preparation and their use.

Abstract: Pyrrole derivatives of the general formula I ##STR1## wherein R denotes alkyl which is substituted by --NH.sub.2 or acylamino, R.sup.1 and R.sup.2 independently of one another denote hydrogen or alkyl having 1 to 4 carbon atoms, R.sup.3 denotes hydrogen, alkyl having 1 to 4 carbon atoms or a carboxylic acid grouping, R.sup.

Abstract: 2,5-Dimethylpyrrole derivatives of the formula I ##STR1## in which R denotes alkyl which is substituted by --NH.sub.2, acylamino of the formula--NH--CX--R.sup.1or by an optionally substituted heterocycle having 1 hetero member; or denotes an optionally substituted heterocycle having 1 member, and X and R.sup.1 have the meanings givenand their pharmacologically acceptable acid addition salts, their preparation by reaction of amines of the formula IIR--NH.sub.2 (II)with acetonylacetone or by acylating N-aminoalkyl-2,5-dimethylpyrroles, and their use as pharmaceutical active compounds.

Abstract: Substituted 4,5-dihydro-3(2H)-pyridazinones of the formula I ##STR1## wherein R, for example, denotes a radical of the formula ##STR2## R.sup.1 and R.sup.2, for example, denote hydrogen or methyl, R.sup.3, for example, denotes 2-methoxy-ethoxy, 3-pyridyl-methoxy, amino-carbonyl-methoxy, hydroxy-carbonyl-methoxy, methyl-thio, (2-methoxy-ethyl)-amino-carbonyl-methoxy, 3-pyridyl-methyl or 5-methyl-1,3,4-oxadiazol-2-yl and R.sup.4, for example, denotes hydrogen, have useful pharmacological properties and can therefore be used for the preparation of pharmacological products.

Abstract: 2-(Aminoalkyl)-pyrrole derivatives of the formula ##STR1## wherein R denotes hydrogen, alkyl or phenyl, R.sup.1 denotes, for example, hydrogen, alkyl, alkoxy-carbonyl, aryl, substituted aryl or heteroaryl, R.sup.2 and R.sup.3 denote, for example, hydrogen, alkyl, alkanoyl, arylcarbonyl, heteroarylcarbonyl or arylenedicarbonyl and n denotes 1, 2 or 3, and their acid addition salts, are used as pharmacological active compounds for combating cerebral aging processes.

Abstract: Tetrahydropyridazinones of the formula I ##STR1## wherein R denotes an optionally substituted carbocyclic or heterocyclic radical, R.sup.1 denotes hydrogen; alkyl; aralkyl, which is optionally substituted in the aryl part; or acyl, and R.sup.2 denotes hydrogen; alkyl, which can optionally be substituted; or optionally substituted phenyl; and their acid addition compounds, if these can be prepared.The tetrahydropyridazinone derivatives of the formula I according to the invention and their physiologically acceptable salts exhibit useful pharmacological actions.

Abstract: The subject matter of the invention is the new 2-azido-3-benzyloxy-propionic acid benzyl ester which is a valuable intermediate product for the production of D,L-serine or derivatives of D,L-serine. The new compound is produced by reacting 2-chloroacrylonitrile with twice the molar amount of benzyl alcohol to form 3-benzyloxy-2-chloropropionic acid imino benzyl ester, saponifying this with acid to form 3-benzyloxy-2-chloropropionic acid benzyl ester, and finally exchanging the chlorine atom by means of an alkali metal azide in the presence of a phase transfer catalyst for an azido group.